Why Vir Biotechnology, Inc.’s (VIR) Stock Is Down 5.68%
As of Thursday, September 24, Vir Biotechnology, Inc.’s VIR share price has dipped by 5.68%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company’s preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Commentary & Analysis
Why Vir Biotechnology, Inc.’s (VIR) Stock Is Up 5.80%
As of Thursday, September 17, Vir Biotechnology, Inc.’s VIR share price has surged by 5.80%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Vir Biotechnology, Inc.’s (VIR) Stock Is Up 5.12%
As of Tuesday, September 01, Vir Biotechnology, Inc.’s VIR share price has surged by 5.12%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Vir Biotechnology, Inc.’s (VIR) Stock Is Up 6.05%
As of Tuesday, August 25, Vir Biotechnology, Inc.’s VIR share price has surged by 6.05%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Vir Biotechnology, Inc.’s (VIR) Stock Is Up 6.08%
As of Friday, August 21, Vir Biotechnology, Inc.’s VIR share price has surged by 6.08%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | VIR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,814.0 | $261.1 | 53% |
|
| Shares Out (Mil) | 168.9 | 54.3 | 73% |
|
| Institutional Ownership | 94.3% | 92.9% | 65% |
|
| Float (Mil) | 129.8 | 41.5 | 66% |
|
| Beta | 1.59 | 0.95 | 85% |
|
| Avg Daily Volume (000s) | 2,419 | 677 | 83% |
|
| Price Change (52-week) |
107.4% | 51.8% | 94% |
|
| Growth | VIR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (2.1%) | 13.2% | 13% |
|
| Net Income (5yr) | (8.0%) | (10.1%) | 31% |
|
| EPS (5yr) | (4.7%) | 15.8% | 25 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (17.1%) | (15.6%) | 41% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | ($0.732) | ($1.755) | ($2.487) | |
| Month Ago EPS | ($0.745) | ($1.780) | ($2.493) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.806) | ($1.373) | ($2.323) | |
| Year/Year Chg | (255.7%) | (44.5%) | (38.2%) | |
| Financials | VIR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $303 | $37 | 36% |
|
| Net Income (TTM) (Mil) | ($252) | ($43) | 6% |
|
| EPS (TTM) | ($1.697) | ($1.600) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($203) | ($32) | 4% |
|
| Net Cash Flow (TTM) (Mil) | ($19) | $2 | 26% |
|
| Long-Term Debt (Q1) (Mil) | $84 | $4 | 43% |
|
| Enterprise Value (Q1) (Mil) | $1,216 | $174 | 43% |
|
| Valuation | VIR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.85 | 2.52 | 49% |
|
| P/E | na | 19.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | VIR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (59.4%) | 68.9% | 2% |
|
| Net Margin | (83.0%) | (72.5%) | 9% |
|
| ROA | (20.9%) | (47.5%) | 20% |
|
| ROE | (26.1%) | (54.9%) | 21% |
|
| Liabilities to Assets | 19.1% | 29.4% | 12% |
|
| F-Score | 4 | 3 | 33% |
|
Vir Biotechnology, Inc. did not pass any screens on 9/24/2026.
